Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) shot up 6.4% on Thursday. The company traded as high as $3.70 and last traded at $3.7350. Approximately 291,380 shares traded hands during trading, a decline of 90% from the average session volume of 3,035,140 shares. The stock had previously closed at $3.51.
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Robert W. Baird increased their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. The Goldman Sachs Group raised their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Wolfe Research started coverage on shares of Taysha Gene Therapies in a research report on Thursday, September 17th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.77.
Read Our Latest Stock Report on Taysha Gene Therapies
Taysha Gene Therapies Trading Down 2.9%
The business has a 50-day moving average of $5.24 and a 200-day moving average of $5.66. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -8.62 and a beta of 1.19.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts forecast that Taysha Gene Therapies, Inc. will post -0.52 earnings per share for the current year.
Institutional Trading of Taysha Gene Therapies
Large investors have recently added to or reduced their stakes in the business. Arizona State Retirement System raised its holdings in shares of Taysha Gene Therapies by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 39,633 shares of the company’s stock valued at $270,000 after purchasing an additional 2,014 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Taysha Gene Therapies by 26.2% during the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after buying an additional 3,362 shares in the last quarter. Sei Investments Co. raised its holdings in Taysha Gene Therapies by 7.6% during the first quarter. Sei Investments Co. now owns 51,472 shares of the company’s stock valued at $230,000 after buying an additional 3,614 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Taysha Gene Therapies by 2.5% in the first quarter. Chicago Partners Investment Group LLC now owns 170,751 shares of the company’s stock worth $763,000 after buying an additional 4,210 shares during the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of Taysha Gene Therapies by 34.5% in the first quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock worth $127,000 after buying an additional 7,296 shares during the last quarter. 77.70% of the stock is owned by institutional investors.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.
Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.
Featured Articles
- Five stocks we like better than Taysha Gene Therapies
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
- 3 Stocks Delivering Bigger Dividends Despite Market Uncertainty
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
